Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
confirmed that overexpressed SLC1A3 in gastric cancer activates the PI3K/AKT pathway, upregulates the expression levels of Glucose transporter 1 (GLUT1), Hexokinase 2 (HK2), and Lactate dehydrogenase A (LDHA), and promotes the growth of gastric cancer, while treatment with the PI3K/AKT inhibitor LY294002 could inhibit the growth-promoting effect of SLC1A3 overexpression on gastric cancer
The potential risks to the fetus or infant are not well understood, and therefore caution is advised
You have options
Both drugs were examined in the DoHH2 B-cell lymphoma flank xenograft model [103]
US$ 23.04
US$ 20.22
US$ 28.33
US$ 22.79
US$ 26.34
US$ 20.92
US$ 25.57
US$ 23.05
US$ 27.36
